



B. anthracis ANTHRAX LF blocking peptide (CDBP5065)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Conjugate	Unconjugated
Applications	Used as a blocking peptide in immunoblotting applications.
Format	Liquid
Concentration	200 µg/mL
Size	0.05 mg
Preservative	None
Storage	-20°C

BACKGROUND

Introduction	Anthrax infection is initiated by inhalation, ingestion or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF) and edema factor (EF).
Keywords	Anthrax lethal factor; Anthrax lethal toxin endopeptidase component; Anthrax LF; bacillus anthracis lethal factor; Lef; LF;